Jaguar Health, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report (Form 8-K) was filed by Jaguar Animal Health, Inc. on July 2, 2015. The report details corporate governance actions taken by the Board of Directors regarding executive compensation and equity incentives.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on personnel compensation adjustments and stock option grants.
Material Changes
The Board approved the following changes, retroactively effective as of June 15, 2015:
- CEO Lisa A. Conte: Base salary increased from $400,000 to $440,000. Target bonus remains 30% of base salary.
- CFO/COO John A. Kallassy: Base salary increased from $245,000 to $286,500. Target cash bonus increased from 30% to 35% of base salary.
- EVP Steven R. King: Base salary increased from $255,000 to $280,500. Target bonus remains 30% of base salary.
- Stock Incentive Plan: Authorized share pool increased by 550,000 shares (from 333,333 to 883,333 total), subject to stockholder approval.
- Contingent Options: 345,141 options granted to employees (including executives) contingent on stockholder approval. Exercise price is $5.09 per share, vesting monthly over 3 years.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary on business performance. The primary contingency noted is that the increase in the stock option pool and the associated option grants are subject to necessary stockholder approval.
Investor Verification Checklist
- Verify if stockholders have approved the increase in the 2014 Stock Incentive Plan pool to 883,333 shares.
- Confirm the final vesting schedule and exercise terms for the 345,141 contingent options granted.
- Review the impact of the retroactive salary increases on the company's operating expenses for the fiscal period ending June 30, 2015.